Mental Help Net
Medications
Resources
Basic InformationMore InformationLatest News
Glaucoma Drugs May Play Role in Longer LifeH1N1 Vaccination Still Highly RecommendedThe Lancet Retracts Study Linking MMR Vaccine, AutismXiaflex Approved for Rare Hand ConditionAntidepressants After Stroke May Boost Mental AbilityFDA Revises Label for the HIV Drug DidanosineFake Drugs Bought on the Web Pose Big Health RisksRotavirus Vaccine Could Save Millions of Children WorldwideVictoza Sanctioned for Type 2 DiabetesMail-Order Pharmacy Use May Improve Drug AdherenceTylenol Recall in Effect Includes Several Other DrugsOverdoses From Prescription Painkillers on the RiseMetformin May Worsen Peripheral NeuropathyTylenol Recall Expands to Include Other OTC MedsLeading COPD Drug Won't Harm Heart: FDAMail-Order May Help People Stick to Med RegimensAngiotensin Receptor Blockers May Help Prevent DementiaNew Anti-Clotting Drug Outperforms PlavixNewer Drug More Effective in Psoriasis TreatmentWhy Antidepressants Don't Work for EveryoneActemra Approved for Rheumatoid ArthritisCelebrex Might Thwart Inherited Skin CancersOlder Antidepressant May Treat Heart FailureAs Swine Flu Wanes, Don't Be FooledCombining Psychotropic Drugs Becoming More CommonAlzheimer's 'Cocktail' Shows PromiseAntidepressants Less Effective for Mild, Moderate SymptomsSeverely Depressed Gain Most from AntidepressantsAcetaminophen Use Not Linked to Major Birth DefectsChanges Made to Adult Vaccination GuidelinesUsing Kitchen Spoons Ups Risk of Dosing ErrorsIn U.S., Prescription Drug Abuse Is GrowingNew Weapon May Help Battle Bird FluDrug Treatments Compared in Bipolar DisorderH1N1 Flu Waning, but Many Vaccine Doses UnusedLithium Beats Valproate for Long-Term Bipolar TherapyNearly 5 Million Doses of Nasal Swine Flu Vaccine RecalledContraceptive Depo-Provera May Weaken BonesAs Swine Flu Wanes, So Does Public's FearThe 'Pill' Offers Benefits Beyond Birth ControlScientists Spot Source of Hurdle to AIDS VaccineSpiriva Inhaler Approved To Reduce Flares of COPDInformation Offered on Effect of H1N1 Vaccine SchedulesNon-Safety, Voluntary Recall of H1N1 Flu Vaccine IssuedGeneric Aricept Approved for Alzheimer's DementiaContraindications to Beta Blockers Linked to DeathsLong-Acting Zyprexa ApprovedSSRIs Linked to Upper Gastrointestinal BleedingBlood Thinner Combos Risky for Heart Attack PatientsPatients Often Lack Knowledge of Their Own Medications
Questions and AnswersBlog EntriesVideosLinksBook Reviews
Community

Talk about this issue in our mental health support community

Therapist Search
Find a Therapist:
 (USA/CAN only)

Use our Advanced Search to locate a therapist outside of North America.

Related Topics

Anxiety Disorders
Depression: Major Depression & Unipolar Varieties
Medical Disorders
Mental Disorders
Mental Health Professions

Arthritis Drugs Unlikely to Increase Cancer Risk

HealthDay News
by -- A. Agrawal, PhD
Updated: Nov 9th 2009

new article illustration

MONDAY, Nov. 9 (HealthDay News) -- Rheumatoid arthritis (RA) patients who start taking anti-tumor necrosis factor α (anti-TNFα) drugs are not likely to have a higher risk of developing cancer than other groups of RA patients, according to a Swedish study in the November issue of Arthritis & Rheumatism.

Johan Askling, M.D., of Karolinska University Hospital at Solna in Stockholm, Sweden, and colleagues compared the risk of cancer in 6,366 RA patients newly being prescribed anti-TNFα treatment, 61,160 biologics-naive RA patients, 5,989 RA patients being prescribed methotrexate, 1,838 RA patients starting disease-modifying antirheumatic drug combination therapy, and the general population of Sweden.

During 25,693 person-years of follow-up, the researchers diagnosed 240 first cancers among RA patients taking anti-TNFα drugs. The risk of cancer was similar in all four groups of RA patients, with a relative risk of approximately 1.0. The relative risks did not increase with increasing time since starting anti-TNFα treatment or the total treatment time. During the first year of treatment, there was a lower risk of cancer in patients who first took etanercept and a higher risk in patients who first took infliximab or adalimumab, but these differences disappeared after one year.

"During the first six years after the start of anti-TNF therapy in routine care, no overall elevation of cancer risk and no increase with follow-up time were observed," the authors conclude.

ARTIS, the Swedish Biologics Register, which supported the study, received maintenance funding from several pharmaceutical companies, and several of the authors reported financial and consulting relationships with pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)

Follow us on Twitter!

Find us on Facebook!




Powered by CenterSite.Net